such as photosynthesis inhibition and MAPK signaling, in the resistant cultivar, alongside heightened enzyme activities and reduced ROS levels, contributing to its resilience. The research further ...

VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer.